FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia

Season 9 Episode 34  ·  Oct 16, 2023, 08:15 PM

Headliner
Share
Subscribe

Dr Kuykendall discusses the FDA approval of momelotinib in myelofibrosis with anemia, key data from the MOMENTUM trial, and how momelotinib alters the myelofibrosis treatment paradigm.

Share
Subscribe
Next
Hasanuma Highlights the Benefits of Building Authentic Connections Through Mentorship
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air